Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

JMP bumps Crinetics shares target on strong PATHFNDR study results

EditorEmilio Ghigini
Published 03/20/2024, 04:27 AM
© Reuters.
CRNX
-

On Wednesday, JMP Securities adjusted its share price target for Crinetics Pharmaceuticals (NASDAQ:CRNX), increasing it to $80 from the previous $60, while maintaining a Market Outperform rating. This change comes in light of recent clinical trial data that has surpassed expectations.

Crinetics Pharmaceuticals has reported notable findings from their PATHFNDR-2 study, which showed an IGF-1 response rate that exceeds that of current injectable somatostatin receptor ligands (SRLs).

The data indicated a consistency in response rates among patients who had previously been on SRLs, with an 80% responder rate compared to 79% in a similar population in the PATHFNDR-1 study. Treatment-naïve patients also demonstrated a 43% response rate, a significant improvement over the 2% for placebo.

The company's investigational drug, paltusotine, has shown rapid effectiveness, with IGF-1 reductions observed as early as two weeks into treatment, a significant advantage over injectable SRLs which can take months to show a response. The safety profile of paltusotine has been positively received, with no discontinuations due to adverse events (AEs), no new safety concerns, and a 97% patient enrollment rate into the open-label extension phase.

The promising results from both PATHFNDR studies have led JMP Securities to anticipate a high likelihood of approval for paltusotine. If approved, paltusotine would be the first once-daily oral medication available for acromegaly, with an efficacy profile that is considered superior to existing treatments.

The convenience of an oral drug is expected to attract a significant number of patients, particularly those who are not achieving optimal disease control with current SRLs.

Based on these outcomes, JMP Securities predicts a strong market performance for paltusotine, with peak worldwide sales now estimated to reach $840 million, a substantial increase from the previous forecast of $450 million. This optimistic sales projection reflects the anticipated demand for a more convenient and effective treatment option for acromegaly patients.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.